Weidong Han, J Stem Cell Res Ther 2017, 7:3(Suppl)
http://dx.doi.org/10.4172/2157-7633.C1.023

T-cell–based therapeutic modality in solid tumours

Weidong Han
Chinese PLA General Hospital, China

The clinical successes of CD19-targeted chimeric antigen receptor (CAR) T-cell treatment in B-cell lineage hematopoietic malignancies in recent years, especially in acute lymphocytic leukemia (ALL), have shown that tumour cells can be precisely and efficiently targeted and eliminated by tumour-associated antigen-redirected immune cells. However, consideration of the significant differences between liquid and solid tumours is needed to ascertain rational, feasible, and efficient CAR T-cell–based therapeutic modalities in solid tumours. How to precisely instruct transfused CAR T cells to attack tumour cells growing outside of normal circulation is still a great challenge. Herein, we would like to briefly introduce CD20-, CD30-directed CAR T trials in patients with refractory lymphomas, and will emphatically address the results from our clinical trial data in patients with relapsed/refractory solid tumours treated by autoglous *EGFR*-, HER2-, and CD133-directed CAR T-based therapeutic modality.

Biography

Weidong Han, MD, PhD, is the Director of Department of Molecular Immunology/Bio-therapeutics, Director of Department of Stem Cell and Tissue Regeneration in Chinese PLA General Hospital. He is a pioneer in the field of tumor immunotherapy, who initially developed the clinical translation of chimeric antigen receptor T (CART) cells in China. He holds 10 projects of clinical trial, including 8 registered CART-based trials (CART19, CART20, CART30, CART33, CART*EGFR*, CART-HER-2, and CART-138). The patents were also applied or obtained in China. In recent 10 years. He obtained 9 grants in China and published more than 80 papers in international journals.

hanwdrsw69@yahoo.com

Notes: